Illumina

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.

These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.

Illumina, established in 1998 and headquartered in United States, North America., specializes in Late Stage Venture, Early Stage Venture, Seed investments across Biotechnology, Biopharma, Genetics, Nanotechnology, Health Diagnostics, Financial Services, Intellectual Property, Venture Capital, Finance, Financial Exchanges. The organization boasts a portfolio of 20 investments, with an average round size of $86.0M and 7 successful exits. Their recent investments include Oxford Nanopore Technologies, IP Group, Invesco, Lansdowne Partners, Genizon BioSciences. The highest investment round they participated in was $137.3B. Among their most notable exits are Oxford Nanopore Technologies and IP Group. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.